Erez Chimovits - 05 Aug 2026 Form 4 Insider Report for Braveheart Bio, Inc. (BRVE)

Reporting relationship: Director, 10%+ Owner
Issuer ticker: BRVE
Reported as of: 05 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 07 Aug 2026, 16:31:24 UTC
Prior SEC filing: 11 Jun 2026
Next SEC filing: 11 Aug 2026
Source filing: View source filing
Reporting owner signature: /s/ James Paul Rickey, Attorney-in-Fact

Key filing fact

Erez Chimovits filed Form 4 for Braveheart Bio, Inc. (BRVE) on 07 Aug 2026.

Key facts

This page summarizes Erez Chimovits's Form 4 filing for Braveheart Bio, Inc. (BRVE).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 07 Aug 2026, 16:31.

Change

Previous filing in this sequence was filed on 11 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001706399 Primary reporting owner

Chimovits Erez

Relationship: Director, 10%+ Owner
Address: C/O BRAVEHEART BIO, INC., ONE LETTERMAN DR., BLDG. A, SUITE A4-300, SAN FRANCISCO
Signature: /s/ James Paul Rickey, Attorney-in-Fact
Signature date: 07 Aug 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BRVE transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +30,000
Change %
Price: $0.000000^*
Shares after: 30,000
Date: 05 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,000
Exercise price: $18.00
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares underlying the stock option will vest in full upon the earlier of (i) August 5, 2027 or (ii) the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service to the Issuer through such vesting date.

Footnote F2

Pursuant to an agreement with OrbiMed Advisors LLC, the Reporting Person is obligated to transfer any securities issued under any such stock options or other awards, or the economic benefit thereof to OrbiMed Advisors LLC, which will in turn ensure that such securities or economic benefits are provided to OrbiMed Private Investments IX, LP.